TUM Klinikum rechts der Isar / CCC München
Munich's technical university hospital, one half of the Comprehensive Cancer Center Munich and a leader in PSMA imaging and radiopharmaceutical chemistry.
Overview
The Klinikum rechts der Isar is the university hospital of the Technical University of Munich and, with the LMU, forms the CCC München, a German Cancer Aid Oncology Center of Excellence and DKTK partner site. Its nuclear medicine and radiopharmacy groups developed the radiohybrid PSMA ligands (rhPSMA) that became flotufolastat F-18, and run large theranostic programmes in prostate and neuroendocrine cancer. The TranslaTUM centre houses translational oncology, imaging and immunology, and the hospital has strong pancreatic surgery, haematology and gastrointestinal oncology programmes. Patients access molecular tumour boards and early-phase trials across both Munich university sites.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to TUM Klinikum, including child institutions. 535 works · 4,676 citations · 69% open access · 7% clinical trials · 2% reviews.
- İhsan Ekin Demir68 works
- Katja Steiger41 works
- Helmut Frieß41 works
- Maximilian Reichert40 works
- Dieter Saur40 works
- Guralp Onur Ceyhan37 works
- Roland Michael Schmid34 works
- Hana Algül32 works
- Helmut Friess29 works
- Rouzanna Istvánffy27 works
- Radiopharmaceutical chemistry and PSMA theranostics
- TranslaTUM
- Pancreatic surgery
- Haematology
- CCC München (with LMU)
A German nuclear medicine physician whose 2015 study of gallium-68 PSMA PET scanning for prostate cancer became one of the most-cited papers in the field, and who now leads theranostics research in Munich.
Nuclear medicine physician who established PET response criteria and leads Munich's radiopharmaceutical development pipeline.
Similar pages
not linked directly; found by shared links- PersonPeter Bartenstein
Shares LMU Klinikum München, PSMA PET, Fluorine-18, Radioligand therapy (beta emitters).
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours.
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours.
- InstitutionWest German Cancer Center (WTZ), University Hospital Essen
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, PSMA PET.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares FAPI PET, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, PSMA PET.
- PersonAndrei Iagaru
Shares PET/MRI, FAPI PET, Fluorine-18.
- PersonKen Herrmann
Shares FAPI PET, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours.
- InstitutionAll India Institute of Medical Sciences, New Delhi
Shares FAPI PET, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.